|Videos|September 25, 2017

Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian Cancer

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the efficacy of niraparib (Zejula) on progression-free survival in patients with recurrent ovarian cancer with partial response to the last platinum-based chemotherapy.

Stay up to date on practice-changing data in community practice.

Related to this article

November 13th, 2026

Dr Parikh on the Future of Oncology: AI, Data, and Patients at the Center

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.

November 12th, 2026

Dr Iyer on AI Documentation and Tumor Boards in Neuroendocrine Tumors

Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.

November 12th, 2026

Dr Chauhan on DLL3 Expression and Obrixtamig Outcomes in DAREON-7

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

November 12th, 2026

DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC

Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.

November 9th, 2026

Dr Iyer on Digitizing NCCN Guidelines for AI at the Point of Care

Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.